Literature DB >> 3816927

Renal clearance of sulphinpyrazone in man.

E G Lentjes, F G Russel, C A van Ginneken.   

Abstract

Six healthy young volunteers received a single dose of sulphinpyrazone 200 mg p.o. Plasma concentration and urinary excretion rate curves showed large intersubject variation for sulphinpyrazone and its metabolites. The sulphide metabolite could only be detected in plasma and not before 3-7 h after ingestion. The total recovery in urine of all compounds varied from 30-56% of the dose. In two subjects the mean residence time of sulphinpyrazone was twice as long as in the other subjects (10.4 h compared with 4.6 h), but the area under the plasma concentration-time curve was comparable to that in the others (mean: 3.0 mg X ml-1 X min), indicating that drug absorption was quantitatively similar but delayed. The renal clearance of sulphinpyrazone varied from 14-40 ml X min-1 (mean: 28 ml X min-1). In view of the very high plasma protein binding of sulphinpyrazone, active tubular secretion is the predominant mechanism in its renal clearance. The same holds for the sulphone metabolite, which has a mean renal clearance of 24 ml X min-1, and even more for the p-hydroxysulphinpyrazone metabolite, which has a renal clearance of 118 ml X min-1. No unambiguous evidence was found in favour of concentration-dependent renal clearance of sulphinpyrazone or its metabolites over the concentration range studied. The renal clearance, especially of sulphinpyrazone, appeared to be dependent on urine pH and not on urine flow rate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816927     DOI: 10.1007/bf00613527

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Binding of sulfinpyrazone and its metabolites in human serum and in solutions of human serum albumin.

Authors:  P Jakobsen; A K Pedersen; F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-09

2.  Sulfinpyrazone kinetics after intravenous and oral administration.

Authors:  J B Lecaillon; C Souppart; J P Schoeller; G Humbert; P Massias
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

3.  Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.

Authors:  W Dieterle; J W Faigle; H Mory; W J Richter; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

Review 4.  Mechanisms of action of sulphinpyrazone.

Authors:  R B Wallis
Journal:  Thromb Res Suppl       Date:  1983

5.  The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.

Authors:  E D Maguire; G F Pay; J Turney; R B Wallis; M J Weston; A M White; L C Williams; H F Woods
Journal:  Haemostasis       Date:  1981

6.  The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.

Authors:  G F Pay; R B Wallis; D Zelaschi
Journal:  Haemostasis       Date:  1981

7.  Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

8.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

9.  Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.

Authors:  B Pfister; P Imhof; H Wirz
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

10.  Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione).

Authors:  B B BRODIE; T F YU; J J BURNS; T CHENKIN; B C PATON; J M STEELE; A B GUTMAN
Journal:  Proc Soc Exp Biol Med       Date:  1954 Aug-Sep
View more
  2 in total

1.  High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man.

Authors:  T B Vree; E W Beneken Kolmer; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 2.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.